Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study

The Breast Cancer Index (BCI) HOXB13/IL17BR (H/I) ratio predicts benefit from extended endocrine therapy in hormone receptor-positive (HR+) early-stage breast cancer. Here, we report the final analysis of the Trans-aTTom study examining BCI (H/I)'s predictive performance. BCI results were avail...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2022-05, Vol.28 (9), p.1871-1880
Hauptverfasser:	Bartlett, John M S, Sgroi, Dennis C, Treuner, Kai, Zhang, Yi, Piper, Tammy, Salunga, Ranelle C, Ahmed, Ikhlaaq, Doos, Lucy, Thornber, Sarah, Taylor, Karen J, Brachtel, Elena F, Pirrie, Sarah J, Schnabel, Catherine A, Rea, Daniel W
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Hormonal - therapeutic use Biomarkers Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Chemotherapy, Adjuvant - methods Disease-Free Survival Female Humans Neoplasm Recurrence, Local - drug therapy Prognosis Tamoxifen - therapeutic use Translational Cancer Mechanisms and Therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!